Journal
CYTOTHERAPY
Volume 20, Issue 9, Pages 1155-1163Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jcyt.2018.07.003
Keywords
adoptive immunotherapy; CD3(+)CD56(+) cell; cytokine-induced killer; psoriasis
Categories
Funding
- National Natural Science Foundation of China [81602711]
- key Nursery Project of the Chinese PLA General Hospital [16KMZ05]
Ask authors/readers for more resources
Psoriasis is a chronic inflammatory skin disorder mediated by the cells and molecules of both the innate and adaptive immune systems. Autologous cytokine-induced killer (CIK) cell infusion is considered an effective and safe cancer treatment and is licensed for this use in China. Accumulated evidence indicating that CD3(+)CD56(+) cells are significantly decreased in psoriatic patients prompted us to investigate if the restoration of CD3(+)CD56(+) cells may be beneficial for psoriatic patients. We designed a clinical trial for psoriasis treatment that involved CIK cell infusion because CIK cells include a large amount of CD3(+)CD56(+) T cells (NCT01894373 at www.clinicaltrials.gov). Six patients with severe psoriasis were initially enrolled, and four of them exhibited markedly lower levels of CD3(+)CD56(+) cells in their peripheral blood (PB) relative to healthy donors. CIK cell infusion-associated toxicity was not observed in any infusion. The percentage of CD3(+)CD56(+) cells in the PB markedly increased and the psoriasis area and severity index (PASI) synchronously decreased in four patients with lower CD3(+)CD56(+) cell contents, and two of them obtained a more than 4-month PASI75 after completing a four-cycle treatment. However, a decrease in the CD3(+)CD56(+) cells was observed concomitantly with disease recurrence after short-term amelioration. In contrast, no obvious improvement was observed in the two patients with nearly normal CD3(+)CD56(+) cells in the PB before treatment. These observations suggest that the normalization of the CD3(+)CD56(+) cell level may improve the skin lesions of severe psoriasis and warrant further clinical trials for severe psoriasis using repeated CIK adoptive immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available